Reuters reported that Global Blood Therapeutics $GBT has brought in an investment banker to explore a possible sale, but everything is still up in the air.
Cue the intense Twitter interest.
Global Blood’s lead therapy is for sickle cell disease with a big focus on blood disorders. Novo, meanwhile, has been at work on its hemophilia franchise, though its biggest efforts are for diabetes.
Shares of GBT are up a little more than 20% today, helping swell a market cap of around $1.5 billion. That qualifies this company as a modest-sized takeover target for a company like Novo, which doesn’t do a lot of M&A.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription